A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Yannick AllanorePeter WungChristina SoubraneCorinne EsperetFrederic MarracheRaphael BejuitAmel LahmarZsuzsanna H McMahanChristopher P Dentonnull nullPublished in: Annals of the rheumatic diseases (2020)
NCT02921971.